Oncternal Therapeutics, Inc. announced the initiation of its Phase 3 global registrational study of zilovertamab, ZILO-301 (NCT05431179), for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). The Company obtained its first Institutional Review Board (IRB) approval for the study and expects to promptly begin patient screening and enrollment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.27 USD | +0.85% | -5.81% | -22.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.88% | 24.48M | |
+49.41% | 56.95B | |
+40.49% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics, Inc Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL